CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype

Breza, Thomas S.; Magro, Cynthia M.

doi:10.1111/j.0303-6987.2005.00367.x

Cited by 27 publications

(15 citation statements)

References 27 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before 2007, only two examples of CD34‐positive cutaneous melanomas could be found in the literature 136,137 . Reactivity for CD34 in melanomas of other locations had also rarely been reported 138 .…”

Section: Melanocytic Tumorsmentioning

confidence: 99%

“…Before 2007, only two examples of CD34-positive cutaneous melanomas could be found in the literature. 136,137 Reactivity for CD34 in melanomas of other locations had also rarely been reported. 138 Recently, a series of cutaneous melanomas showing CD34 expression in one third of the 30 cases of invasive melanoma studied has been published.…”

Section: Melanocytic Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

CD34‐reactive tumors of the skin. An updated review of an ever‐growing list of lesions

Tardío

2008

J Cutan Pathol

View full text Add to dashboard Cite

Section: Melanocytic Tumorsmentioning

confidence: 99%

Section: Melanocytic Tumorsmentioning

confidence: 99%

CD34‐reactive tumors of the skin. An updated review of an ever‐growing list of lesions

Tardío

2008

J Cutan Pathol

View full text Add to dashboard Cite

“…Other commonly used vascular markers are factor VIII‐related antigen and CD34. Factor VIII‐related antigen is negative in melanoma; however, though infrequently, melanoma can have strong reactivity for CD34 . Further, it must be kept in mind that CD31, CD34, and/or factor VIII‐related antigen are lost in up to 40% of angiosarcomas, further demonstrating the need for a panel of immunostains.…”

Section: Discussionmentioning

confidence: 99%

Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series

et al. 2017

View full text Add to dashboard Cite

Cutaneous angiosarcoma can be challenging to diagnose particularly when poorly vasoformative and studied on biopsies. We report a case of a cutaneous angiosarcoma with strong positivity for tyrosinase, the first to our knowledge, initially misdiagnosed as melanoma. We subsequently evaluated the reactivity of panmelanocytic cocktail (tyrosinase, HMB-45 and Melan-A), SOX10, tyrosinase and MITF in a large tissue microarray (TMA) of angiosarcoma. The TMA included 142 cases of angiosarcomas (29 cutaneous, 22 primary breast, 41 post-radiation breast, 15 visceral, 26 deep soft tissue and bone, 5 chronic lymphedema-associated and 4 angiosarcomas arising in other sarcomas). Immunohistochemical studies were performed with anti-panmelanocytic cocktail, anti-SOX10, anti-MITF and anti-tyrosinase antibodies. TMA staining results were scored on intensity and percentage of tumoral labeling. Aside from the index case, no cases (0 of 133) showed positivity for tyrosinase including 28 cutaneous angiosarcomas. One breast angiosarcoma (1 of 131) was positive for MITF. All cases were negative for SOX10 and panmelanocytic cocktail (0 of 132). Angiosarcomas can rarely be positive for tyrosinase and MITF. Pathologists should be cognizant of these rare exceptions to prevent confusion with melanoma. Additional immunohistochemical markers for vascular and melanocytic differentiation, thorough histological examination for vasoformative and in situ areas as well as clinical impression are helpful in these exceptionally problematic cases.

show abstract

“…CD34 is a marker commonly seen on hematopoietic cancer stem cells (35) and has more recently been shown be present on tumor-initiating, self-renewing melanoma cells in mouse models (10). Additionally, pathologic analysis of malignant human melanoma biopsies has shown that CD34 is expressed (36,37). ABCB5 is a drug efflux transporter which regulates skin progenitor cell fusion and is a well-known marker of melanoma stem cells.…”

Section: Discussionmentioning

confidence: 99%

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin

Bonchak

Eby

Willenborg

et al. 2014

Archives of Biochemistry and Biophysics

View full text Add to dashboard Cite

Monobenzyl ether of hydroquinone (MBEH) is cytotoxic towards melanocytes. Its treatment efficacy is limited by an inability to eradicate stem cells. By contrast, 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-DPAT) affects melanocyte stem cell survival. MBEH and 8-DPAT were added to melanocytes and melanoma cells to compare cytotoxicity. Stem cell content among viable cells was determined by fluorocytometry using markers CD34, Pax3, and CD271. Immunostaining was used to identify stem cells in skin explants treated with MBEH or 8-DPAT ex vivo. Mice were exposed to MBEH or 8-DPAT and scanned for depigmentation before harvesting skin. MBEH exposure prompted a relative increase in stem cells among cultured melanocytes and melanoma cells, as treatment preferentially eliminated differentiated cells and spared the stem cells. Viability of this remaining, enriched stem cell population was however rapidly reduced by exposure to 8-DPAT within melanocyte and melanoma cell cultures. In human skin explants, the abundance of melanocyte stem cells was also visibly reduced after 8-DPAT treatment, in contrast to tissue exposed to MBEH. Meanwhile, significant depigmentation of the mouse pelage and loss of differentiated melanocytes was observed in vivo in response to topical application of MBEH, but not 8-DPAT. Prolonged application of the latter agent instead appeared to effectively reduce the abundance of melanocyte stem cells in the dermis. This furthers the idea that MBEH and 8-DPAT target complementary cell populations. Results indicate that combination treatment may demonstrate superior therapeutic activity by eliminating both differentiated and tumor initiating populations.

show abstract

CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype

Cited by 27 publications

References 27 publications

CD34‐reactive tumors of the skin. An updated review of an ever‐growing list of lesions

CD34‐reactive tumors of the skin. An updated review of an ever‐growing list of lesions

Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin

Contact Info

Product

Resources

About